Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Sponsor
Alcon Research (Industry)
Overall Status
Completed
CT.gov ID
NCT00346866
Collaborator
(none)
136
1
19
7.1
Study Details
Study Description
Brief Summary
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Study Start Date
:
May 1, 2000
Actual Primary Completion Date
:
Dec 1, 2001
Actual Study Completion Date
:
Dec 1, 2001
Outcome Measures
Primary Outcome Measures
- Mean change from the baseline in logMAR visual acuity score at Month 6 []
Secondary Outcome Measures
- % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV. []
Eligibility Criteria
Criteria
Ages Eligible for Study:
50 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- AMD disease
Exclusion Criteria:
- Age
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Facility | Beachwood | Ohio | United States | 44122 |
Sponsors and Collaborators
- Alcon Research
Investigators
- Study Director: Patricia Zilliox, Alcon Research
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00346866
Other Study ID Numbers:
- C-00-07
First Posted:
Jun 30, 2006
Last Update Posted:
Aug 5, 2008
Last Verified:
Aug 1, 2008
Additional relevant MeSH terms: